ASX ANNOUNCEMENT 5 September 2017

Cynata to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York Melbourne, Australia; 5 September 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference. The conference is being held on September 10-12, 2017 in New York City.

The Rodman & Renshaw conference is sponsored by H. C. Wainwright & Co., a leading Wall Street investment bank, with a strong reputation in life sciences. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.

Dr Ross Macdonald, Managing Director and CEO, will provide an overview of the Company and its unique Cymerus™ platform during the live presentation and will also be participating in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend the conference. A copy of the presentation will be made available on Cynata's website.

If you are an institutional investor, and would like to attend the Company's presentation, please visit the Rodman & Renshaw website to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 19th Annual Rodman & Renshaw Global Investment Conference Date: September 11, 2017 Time: 3:00pm (US Eastern Time) Location: Holmes II Room; Lotte New York Palace Hotel in New York City Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com

Daniel Paproth, Australia Media Contact, 0421 858 982 , daniel.paproth@mcpartners.com.au Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.

Cynata Therapeutics Limited

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia PO Box 7165, Hawthorn North, Victoria 3122

T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com

ABN - 98 104 037 372

Cynata Therapeutics Ltd. published this content on 05 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 04 September 2017 23:57:06 UTC.

Original documenthttp://cynata.com/wp-content/uploads/2017/09/17.09.05.Cynata-to-Present-at-Rodman-Renshaw-Investor-Conference.pdf

Public permalinkhttp://www.publicnow.com/view/66F5175ABB30E6AE2A3215B17D19CF623CB679B7